|1.||Køber, Lars: 12 articles (01/2011 - 01/2002)|
|2.||Torp-Pedersen, Christian: 11 articles (01/2011 - 01/2002)|
|3.||Brendorp, Bente: 10 articles (04/2010 - 01/2002)|
|4.||Vos, Marc A: 9 articles (01/2015 - 08/2003)|
|5.||Torp-Pedersen, C: 7 articles (02/2003 - 08/2000)|
|6.||Køber, L: 7 articles (02/2003 - 10/2000)|
|7.||Naccarelli, Gerald V: 6 articles (05/2014 - 03/2003)|
|8.||Wolbrette, Deborah L: 6 articles (05/2014 - 03/2003)|
|9.||Beekman, Jet D M: 6 articles (11/2012 - 11/2006)|
|10.||Seibaek, Marie: 5 articles (04/2010 - 03/2004)|
01/01/2000 - "There was no significant reduction in the Danish multicenter study of Dofetilide to convert the atrial fibrillation (AF) to a normal rhythm in the 25% of the CHF patients who had AF (EDR was 224 in the placebo group and 216 in the Dofetilide group). "
09/16/1999 - "Once sinus rhythm was restored, dofetilide was significantly more effective than placebo in maintaining sinus rhythm (hazard ratio for the recurrence of atrial fibrillation, 0.35; 95 percent confidence interval, 0.22 to 0.57; P<0.001). "
02/01/1997 - "This study sought to determine the safety and efficacy of a single bolus of intravenous dofetilide, a pure class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. "
12/01/1999 - "Preliminary findings from the EMERALD (European and Australian Multicenter Evaluative Research on Atrial Fibrillation Dofetilide) and SAFIRE-D (Symptomatic Atrial Fibrillation Investigation and Randomized Evaluation of Dofetilide) studies suggest that oral dofetilide is effective in the conversion of atrial fibrillation or flutter to sinus rhythm. "
01/01/2007 - "Oral dofetilide is effective in the conversion of atrial fibrillation and flutter to sinus rhythm and in the maintenance of sinus rhythm after conversion. "
01/01/2004 - "Dofetilide may also be capable of restoring sinus rhythm in up to 25-30% of patients and can be used in patients with heart failure. "
09/01/2003 - "In addition, dofetilide therapy was associated with a significantly lower risk ratio versus placebo for either all-cause (RR, 0.70; 95% CI, 0.56 to 0.89; P < or = 0.005) or congestive heart failure (RR, 0.69; 95% CI, 0.51 to 0.93; P < or = 0.02) rehospitalization. "
05/01/2002 - "However, as the positive inotropic effect is not observed with clinically relevant concentrations at a physiological rate in heart failure, dofetilide is unlikely to be useful as a positive inotrope in the treatment of heart failure."
05/01/2002 - "The aim was to test whether dofetilide has some potential for use in the treatment of heart failure. "
03/01/2002 - "Effect of dofetilide on QT dispersion and the prognostic implications of changes in QT dispersion for patients with congestive heart failure."
|3.||Atrial Flutter (Flutter, Atrial)
09/01/1996 - "Even if dofetilide proves highly effective for human atrial flutter, its safety will need to be proven in large clinical trials. "
09/01/1996 - "The fact that these, and previous, data indicate a specific beneficial effect of dofetilide, particularly on atrial flutter, is interesting. "
09/01/1996 - "Dofetilide slowed atrial flutter by 37% (P = 0.003) prior to terminating and suppressing it in all dogs. "
01/01/1996 - "Use of intravenous dofetilide in atrial flutter with hemodynamic instability."
09/01/1996 - "Perhaps dofetilide will be effective for certain types of atrial flutter requiring an anatomical center defined by an area of injury or surgical scar in the right atrium. "
|4.||Cardiac Arrhythmias (Arrythmia)
10/01/2009 - "The remaining 17 were discharged taking dofetilide, with either resolved or improved arrhythmia. "
09/16/1999 - "Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group."
11/15/1995 - "Dofetilide Arrhythmia Study Group."
03/01/2015 - "We determined whether pharmacologic conversion with dofetilide predicts long-term arrhythmia-free survival. "
08/01/2011 - "Dofetilide is approved for use for atrial arrhythmias and has not been studied for ventricular arrhythmia suppression. "
11/15/1995 - "Electrophysiologic profile and efficacy of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with sustained monomorphic ventricular tachycardia. "
11/15/1995 - "This open study evaluated the acute electrophysiologic effects, antiarrhythmic efficacy, and safety of different doses of intravenous dofetilide, a new class III drug, in 50 patients with sustained monomorphic ventricular tachycardia inducible by programmed electrical stimulation who had previously been unsuccessfully treated with 0 to 7 (median 3) other drugs. "
09/01/1995 - "We developed a dose-ranging, placebo-controlled study design to define the range of effective doses and to evaluate the clinical electrophysiology of intravenous dofetilide in patients in whom sustained ventricular tachycardia or fibrillation was reproducibly inducible at baseline electrophysiologic testing. "
10/20/2015 - "Spontaneous early afterdepolarizations (EADs) and ventricular tachycardia/fibrillation occurred in 50% of hearts at 2.7 mmol/L [K] in the absence of dofetilide and 3.3 mmol/L [K] in its presence. "
11/01/2014 - "In this review, we discuss the underlying mechanism, risk factors and precautionary measures to avoid dofetilide induced QT prolongation and ventricular tachycardia/Tdp. "
|5.||Sotalol (Sotalol Hydrochloride)
|10.||1- (methanesulfonamido- 1- naphthyloxy)- 2- (N- (4- methane sulfonamidophenethyl)-N-acetamido)ethane
|1.||Electric Countershock (Cardioversion)
|2.||Coronary Artery Bypass (Coronary Artery Bypass Surgery)
|3.||Drug Therapy (Chemotherapy)
|4.||Implantable Defibrillators (Implantable Cardioverter-Defibrillator)